Journal article

Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity

Curr.Opin.Investig.Drugs, vol. 7, issue 10 (2006) pp. 924-935

  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.
Sign in to save reference

Abstract

Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed

Author-supplied keywords

  • Adverse effects
  • Anti-Obesity Agents
  • Clinical Trials,Phase I as Topic
  • Clinical Trials,Phase II as Topic
  • Diabetes Mellitus,Type 2
  • Hexoses
  • Humans
  • Hypoglycemic Agents
  • Structure-Activity Relationship
  • animals
  • contraindications
  • drug therapy
  • metabolism
  • obesity
  • pharmacokinetics
  • therapeutic use
  • toxicity

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • PMID: 17086938

Authors

  • M C Moore

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free